Merck explores oncology and other conjugates in $300m deal with Ambrx
09:20 EDT 15 Jun 2012 | SCRIP
Ambrx will get $15 million upfront and up to $288 million in milestone payments, plus royalties, from its collaboration with Merck to discover and develop an undisclosed number of biologic drug conjugates directed at.....
Original Article: Merck explores oncology and other conjugates in $300m deal with Ambrx
More From BioPortfolio on "Merck explores oncology and other conjugates in $300m deal with Ambrx"
Biotech & Healthcare Channels
World News
Life Science Events
Corporate Database
Market Reports
Categories
Search BioPortfolio:
